# US 2024/0254481 A1 · Extracellular vesicle-aso constructs targeting stat6

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254481 A1
- Document ID: US20240254481A1
- Status: Published application
- Kind: A1
- Application number: 18/050,017
- Filed: 2022-10-26
- Published: 2024-08-01
- Earliest claimed: 0001-01-01
- Assignees: Lonza Sales AG
- Applicants: Lonza Sales AG
- Inventors: Dalia BURZYN; Sushrut KAMERKAR; Adam T. BOUTIN; Wendy BROOM; Sriram SATHYANARAYANAN; Ajay VERMA
- Web page: https://patentgrep.com/patent/US20240254481A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/3511: intercalating or cleaving agent
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a STAT6 transcript. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.

## Claims

### Claim 1

An extracellular vesicle comprising an antisense oligonucleotide (ASO), which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length, wherein the contiguous nucleotide sequence is the nucleotide sequence as set forth in SEQ ID NO: 185.

### Claim at position 2

2-15. (canceled)

### Claim 16 (depends on 1)

The extracellular vesicle of claim 1, wherein the ASO has the design of LLLDnLLL, wherein “n” is 14, “L” is an LNA, and wherein “D” is a DNA.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The extracellular vesicle of claim 1, wherein all of the cytosine nucleobases in the ASO are 5′-methyl-cytosine nucleobases.

### Claim at position 6

19-25. (canceled)

### Claim 26 (depends on 1)

The extracellular vesicle of claim 1, wherein the ASO is 20 nucleotides in length.

### Claim at position 8

27-30. (canceled)

### Claim 31 (depends on 1)

The extracellular vesicle of claim 1, which further comprises an anchoring moiety.

### Claim 32 (depends on 31)

The extracellular vesicle of claim 31, wherein the ASO is linked to the anchoring moiety.

### Claim 33 (depends on 1)

The extracellular vesicle of claim 1, further comprising an exogenous targeting moiety.

### Claim 34 (depends on 33)

The extracellular vesicle of claim 33, wherein the exogenous targeting moiety comprises a peptide, an antibody or an antigen-binding fragment thereof, a chemical compound, an RNA aptamer, or any combination thereof.

### Claim 35 (depends on 33)

The extracellular vesicle of claim 33, wherein the exogenous targeting moiety comprises a peptide.

### Claim at position 14

36-45. (canceled)

### Claim 46 (depends on 1)

The extracellular vesicle of claim 1, which overexpresses a PTGFRN protein or a functional fragment thereof.

### Claim at position 16

47-74. (canceled)

### Claim 75 (depends on 31)

The extracellular vesicle of claim 31, wherein the anchoring moiety comprises sterol, GM1, a lipid, a vitamin, a small molecule, a peptide, or a combination thereof.

### Claim 76 (depends on 31)

The extracellular vesicle of claim 31, wherein the anchoring moiety comprises cholesterol.

### Claim 77

(canceled)

### Claim 78 (depends on 31)

The extracellular vesicle of claim 31, wherein the ASO is linked to the anchoring moiety by a linker.

### Claim 79

(canceled)

### Claim 80 (depends on 78)

The extracellular vesicle of claim 78, wherein the linker is a polypeptide, is a non-polypeptide moiety, or comprises ethylene glycol.

### Claim at position 23

81-82. (canceled)

### Claim 83 (depends on 80)

The extracellular vesicle of claim 80, wherein the linker comprises HEG, TEG, PEG, or any combination thereof.

### Claim 84 (depends on 78)

The extracellular vesicle of claim 78, wherein the linker comprises:
(i) acrylic phosphoramidite (e.g,. ACRYDITE™), adenylation, azide (NHS Ester), digoxigenin (NHS Ester), cholesterol-TEG, I-LINKER™, an amino modifier (e.g., amino modifier C6, amino modifier C12, amino modifier C6 dT, or Uni-Link™ amino modifier), alkyne, 5′ Hexynyl, 5-Octadiynyl dU, biotinylation (e.g., biotin, biotin (Azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), thiol modification (thiol modifier C3 S—S, dithiol or thiol modifier C6 S—S), or any combination thereof;
(ii) valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate;
(iii) (a) a maleimide moiety and (b) valine-alanine-p-aminobenzylcarbamate or valine-citrulline-p-aminobenzylcarbamate; or
(iv) any combination thereof.

### Claim 85 (depends on 78)

The extracellular vesicle of claim 78, wherein the linker is a cleavable linker.

### Claim at position 27

86-87. (canceled)

### Claim 88 (depends on 1)

The extracellular vesicle of claim 1, wherein the extracellular vesicle is an exosome.

### Claim at position 29

89-142. (canceled)

### Claim 143 (depends on 1)

The extracellular vesicle of claim 1, wherein the ASO is linked to cholesterol by a linker comprising TEG and HEG.

### Claim 144

An extracellular vesicle comprising an antisense oligonucleotide (ASO) comprising the nucleotide sequence as set forth in SEQ ID NO: 185, wherein the ASO is 20 nucleotides in length and has the design of LLLDnLLL, wherein “n” is 14, “L” is an LNA, and “D” is a DNA;
wherein all of the cytosine nucleobases in the ASO are 5′-methyl-cytosine nucleobases;
wherein each of the internucleoside linkages in the ASO is a phosphorothioate linkage;
wherein the ASO is linked to an anchoring moiety on the exterior surface of the extracellular vesicle;
wherein the anchoring moiety comprises cholesterol; and
wherein the ASO is linked to cholesterol by a linker comprising TEG and HEG.

### Claim 145 (depends on 144)

The extracellular vesicle of claim 144, wherein the extracellular vesicle is an exosome.
